Altogether, the findings show that formononetin exhibits noteworthy anticancer potential in multiple myelomas that may be chiefly mediated via the ROS-regulated inhibition of STAT3 as well as the STAT5 signaling cascade [45] (Table 1). Here, STAT3 is linked to plasma cell myeloma.